Range of suitable sufferers: CDEC talked about the uncertainty in the amount of patients with reasonably critical to significant hemophilia B in Canada eligible for etranacogene dezaparvovec. Scientific industry experts consulted by CADTH indicated that some patients that are categorized as getting moderate or reasonable disease can have a significant https://hemgenix71582.look4blog.com/74059688/new-step-by-step-map-for-hemgenix